Patents by Inventor Brian Higgins

Brian Higgins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160129033
    Abstract: There are provided pharmaceutical products comprising a) a first component comprising the compound of formula (A); and b) a second component comprising capecitabine for the simultaneous or sequential treatment of cancer, kits comprising said product as well as methods for treating cancer patients by administering said product.
    Type: Application
    Filed: June 16, 2014
    Publication date: May 12, 2016
    Inventors: Brian Higgins, Gwen Nichols, Kathryn E. Packman
  • Patent number: 9295669
    Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: March 29, 2016
    Assignee: Hoffman La-Roche Inc.
    Inventors: Kapil Dhingra, Brian Higgins, Kenneth Kolinsky, Richard J. Lee, Brian Lestini, Kathryn Packman, Fei Su
  • Patent number: 9216170
    Abstract: Treatment of proliferative diseases with a combination of a b-Raf inhibitor and MDM2 inhibitor.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: December 22, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Brian Higgins, Kenneth Kolinsky, Gwen Nichols, Kathryn Packman, Fei Su
  • Patent number: 9126964
    Abstract: The present disclosure provides methods to produce substituted furans (e.g., halomethylfurfural, hydroxymethylfurfural, and furfural), by acid-catalyzed conversion of biomass using a gaseous acid in a multiphase reactor, such as a fluidized bed reactor.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: September 8, 2015
    Assignee: MICROMIDAS, INC.
    Inventors: Makoto N. Masuno, John Bissell, Ryan L. Smith, Brian Higgins, Alex Be. Wood
  • Publication number: 20150202182
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: March 30, 2015
    Publication date: July 23, 2015
    Inventors: Brian Higgins, Gwen Nichols, Lin-Chi Chen
  • Publication number: 20150157603
    Abstract: The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML.
    Type: Application
    Filed: December 4, 2014
    Publication date: June 11, 2015
    Inventors: Brian Higgins, Gwen Nichols, Kathryn E. Packman
  • Publication number: 20150126575
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventors: Kelli Glenn, Brian Higgins, Gwen Nichols, Kathryn Packman
  • Patent number: 8709419
    Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: April 29, 2014
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Kapil Dhingra, Brian Higgins, Kenneth Kolinsky, Richard J. Lee, Brian Lestini, Kathryn Packman, Fei Su
  • Publication number: 20140100378
    Abstract: The present disclosure provides methods to produce substituted furans (e.g., halomethylfurfural, hydroxymethylfurfural, and furfural), by acid-catalyzed conversion of biomass using a gaseous acid in a multiphase reactor, such as a fluidized bed reactor.
    Type: Application
    Filed: June 6, 2012
    Publication date: April 10, 2014
    Applicant: MICROMIDAS, INC.
    Inventors: Makoto N. Masuno, John Bissell, Ryan L. Smith, Brian Higgins, Alex Benjamin Wood, Marc Foster
  • Publication number: 20130245089
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: February 5, 2013
    Publication date: September 19, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Kelli Glenn, Brian Higgins, Gwen Nichols, Kathryn Packman
  • Publication number: 20130245039
    Abstract: Treatment of proliferative diseases with a combination of a b-Raf inhibitor and MDM2 inhibitor.
    Type: Application
    Filed: February 5, 2013
    Publication date: September 19, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Brian Higgins, Kenneth Kolinsky, Gwen Nichols, Kathryn Packman, Fei Su
  • Patent number: 8426798
    Abstract: An electrical termination circuit for a traveling wave optoelectronic device is disclosed. The electrical termination circuit is constructed to reflect a portion of a radio-frequency signal back into the optoelectronic device. The reflected signal is out of phase with the applied radio-frequency signal at a frequency of a detrimental spectral feature or a bump in an electro-optical transfer characteristic of the optoelectronic device. The amplitude and the phase of the reflected signal are selected so as to suppress the detrimental spectral feature without a significant reduction in the efficiency of electro-optical or optical-electrical transformation of the optoelectronic device.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: April 23, 2013
    Assignee: JDS Uniphase Corporation
    Inventors: Brian Higgins, Gregory J. McBrien
  • Publication number: 20120148533
    Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.
    Type: Application
    Filed: December 7, 2011
    Publication date: June 14, 2012
    Inventors: Kapil Dhingra, Brian Higgins, Kenneth Kolinsky, Richard J. Lee, Brian Lestini, Kathryn Packman, Fei Su
  • Publication number: 20120045433
    Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an topoisomerase inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the topoisomerase inhibitor is irinotecan, or a pharmaceutically acceptable salt thereof, and the disorder is colorectal cancer involving a tumor comprising b-Raf having the V600E mutation.
    Type: Application
    Filed: August 10, 2011
    Publication date: February 23, 2012
    Inventors: Kapil Dhingra, Brian Higgins, Kenneth Kolinsky, Richard J. Lee, Brian Lestini, Kathryn Packman, Fei Su
  • Publication number: 20120045434
    Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer.
    Type: Application
    Filed: August 10, 2011
    Publication date: February 23, 2012
    Inventors: Kapil Dhingra, Brian Higgins, Kenneth Kolinsky, Richard J. Lee, Brian Lestini, Kathryn Packman, Fei Su
  • Patent number: 7951405
    Abstract: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and cisplatin combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and cisplatin combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: May 31, 2011
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Brian Higgins, Kenneth Kolinsky
  • Publication number: 20110049335
    Abstract: An electrical termination circuit for a traveling wave optoelectronic device is disclosed. The electrical termination circuit is constructed to reflect a portion of a radio-frequency signal back into the optoelectronic device. The reflected signal is out of phase with the applied radio-frequency signal at a frequency of a detrimental spectral feature or a bump in an electro-optical transfer characteristic of the optoelectronic device. The amplitude and the phase of the reflected signal are selected so as to suppress the detrimental spectral feature without a significant reduction in the efficiency of electro-optical or optical-electrical transformation of the optoelectronic device.
    Type: Application
    Filed: August 19, 2010
    Publication date: March 3, 2011
    Applicants: JDS Uniphase Corporation
    Inventors: Brian Higgins, Gregory J. McBrien
  • Publication number: 20080048832
    Abstract: A radio frequency identification device includes an integrated circuit including a receiver, a transmitter, and a microprocessor. The receiver and transmitter together define an active transponder. The integrated circuit is preferably a monolithic single die integrated circuit including the receiver, the transmitter, and the microprocessor. Because the device includes an active transponder, instead of a transponder which relies on magnetic coupling for power, the device has a much greater range.
    Type: Application
    Filed: August 30, 2007
    Publication date: February 28, 2008
    Inventors: James O'Toole, John Tuttle, Mark Tuttle, Tyler Lowrey, Kevin Devereaux, George Pax, Brian Higgins, David Ovard, Shu-Sun Yu, Robert Rotzoll
  • Publication number: 20080048835
    Abstract: A radio frequency identification device includes an integrated circuit including a receiver, a transmitter, and a microprocessor. The receiver and transmitter together define an active transponder. The integrated circuit is preferably a monolithic single die integrated circuit including the receiver, the transmitter, and the microprocessor. Because the device includes an active transponder, instead of a transponder which relies on magnetic coupling for power, the device has a much greater range.
    Type: Application
    Filed: August 29, 2007
    Publication date: February 28, 2008
    Inventors: James O'Toole, John Tuttle, Mark Tuttle, Tyler Lowrey, Kevin Devereaux, George Pax, Brian Higgins, David Ovard, Shu-Sun Yu, Robert Rotzoll
  • Publication number: 20080030353
    Abstract: A radio frequency identification device includes an integrated circuit including a receiver, a transmitter, and a microprocessor. The receiver and transmitter together define an active transponder. The integrated circuit is preferably a monolithic single die integrated circuit including the receiver, the transmitter, and the microprocessor. Because the device includes an active transponder, instead of a transponder which relies on magnetic coupling for power, the device has a much greater range.
    Type: Application
    Filed: August 29, 2007
    Publication date: February 7, 2008
    Inventors: James O'Toole, John Tuttle, Mark Tuttle, Tyler Lowrey, Kevin Devereaux, George Pax, Brian Higgins, David Ovard, Shu-Sun Yu, Robert Rotzoll